CORS RAM I I INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY To: Marco Poletti Bracco S.p.A. NOTIFICATION OF TRANSMITTAL OF Intellectual Property Department THE INTERNATIONAL PRELIMINARY Via Egidio Folli, 50 **EXAMINATION REPORT** I-20134 Milano **ITALIE** (PCT Rule 71.1) Date of mailing (day/month/year) 24.02.2005 Applicant's or agent's file reference IMPORTANT NOTIFICATION 348-B0496 International filing date (day/month/year) Priority date (day/month/year) International application No. 13.11.2002 11.11.2003 PCT/EP 03/12584

Applicant BRACCO SPA

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:

<u>)</u>))

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 Authorized Officer

Sleex, C

Tel. +49 89 2399-8044



INTERN ONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

| Applicant's or agent's file reference 348-B0496 | | | | FOR FURTHER ACT | HER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) | | | | | |
|--|--|-------------|---------------------------|---|--|---------------------------|--|--|--|--|
| International application No. PCT/EP 03/12584 | | | | International filing date (da 11.11.2003 | national filing date <i>(day/month/year)</i> 11.2003 | | Priority date (day/month/year) 13.11.2002 | | | |
| International Patent Classification (IPC) or both national classification and IPC A61K31/198 | | | | | | | | | | |
| Applicant BRACCO SPA | | | | | | | | | | |
| 1. | This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. | | | | | | | | | |
| 2. | This REPORT consists of a total of 4 sheets, including this cover sheet. | | | | | | | | | |
| | This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). | | | | | | | | | |
| | These annexes consist of a total of sheets. | | | | | | | | | |
| 3. | 3. This report contains indications relating to the following items: | | | | | | | | | |
| | 1 | \boxtimes | Basis of the opinion | | | | | | | |
| | П | | Priority | | | | | | | |
| | Ш | | Non-establishment of o | opinion with regard to nove | elty, in | ventive step a | nd industrial applicability | | | |
| | IV | | Lack of unity of inventi- | on | | | | | | |
| | V Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement | | | | | | ventive step or industrial applicability; | | | |
| | VI | | Certain documents cité | ed | | | | | | |
| | VII | | | nternational application | | | | | | |
| | VIII | | Certain observations o | n the international applica | ation | | | | | |
| | | | | | Onto of | completion of thi | | | | |
| Date of submission of the demand | | | | | Jale OI | completion of thi | s report | | | |
| 11.11.2003 | | | | | | 24.02.2005 | | | | |
| Name and mailing address of the international | | | | | | ed Officer | nes Palan. | | | |
| preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 | | | | | 3üttne ^T elepho | er, U ene No. +49 89 2 | 399-7841 | | | |

INTERNATIONAL PROMINARY EXAMINATION REPORT

10/532447
10/532447
10/532447
10/532447
10/532447
10/532447

I. Basis of the report

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

| | De | scription, Pages | · | | | | | |
|----|---|--|---|--|--|--|--|--|
| | 1-1 | 2 | as originally filed | | | | | |
| | Cla | aims, Numbers | | | | | | |
| | 1-1 | 6 | as originally filed | | | | | |
| 2. | Wit lan | With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. | | | | | | |
| | The | ese elements were av | ailable or furnished to this Authority in the following language: , which is: | | | | | |
| | | the language of a tra | anslation furnished for the purposes of the international search (under Rule 23.1(b)). | | | | | |
| | | the language of pub | lication of the international application (under Rule 48.3(b)). | | | | | |
| | | the language of a translation that the language of a translation 55.2 and/or 55. | anslation furnished for the purposes of international preliminary examination (under 3). | | | | | |
| 3. | 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, international preliminary examination was carried out on the basis of the sequence listing: | | | | | | | |
| | | contained in the inte | rnational application in written form. | | | | | |
| | | filed together with th | e international application in computer readable form. | | | | | |
| | | furnished subsequer | ntly to this Authority in written form. | | | | | |
| | | furnished subsequer | ntly to this Authority in computer readable form. | | | | | |
| | | The statement that t in the international a | he subsequently furnished written sequence listing does not go beyond the disclosure pplication as filed has been furnished. | | | | | |
| | | The statement that t listing has been furn | he information recorded in computer readable form is identical to the written sequence ished. | | | | | |
| 4. | The | The amendments have resulted in the cancellation of: | | | | | | |
| | | the description, | pages: | | | | | |
| | | the claims, | Nos.: | | | | | |
| | | the drawings, | sheets: | | | | | |
| 5. | | This report has been been considered to | established as if (some of) the amendments had not been made, since they have go beyond the disclosure as filed (Rule 70.2(c)). | | | | | |
| | | (Any replacement st report.) | neet containing such amendments must be referred to under item 1 and annexed to this | | | | | |
| 6. | Ado | ditional observations. | f necessary: | | | | | |





- V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- 1. Statement

Novelty (N)

Yes: Claims

8,13,14

No: Claims

1-7, 9-12, 15,16

Inventive step (IS)

Yes: Claims

No: Claims 1-16

Industrial applicability (IA)

Yes: Claims

1-16

No: Claims

2. Citations and explanations

see separate sheet

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- Reference is made to the following document: 1.)
 - D1: SANTINI FERRUCCIO ET AL: 'Thyromimetic effects of 3,5,3'triiodothyronine sulfate in hypothyroid rats' ENDOCRINOLOGY, vol. 133, no. 1, 1993, pages 105-110, XP002272821 ISSN: 0013-7227 cited in the application
- The present application does not meet the criteria of Article 33(1) PCT, because the 2.) subject-matter of claims 1-7, 9-12, 15,16 is not new in the sense of Article 33(2) PCT.

Document D1 discloses that treatment with T3 sulfate leads to a significant correction of several parameters of hypothyroidism. Since the thyromimetic effects of T3S would be self-limiting it is suggested as thyromimetic agent with reduced risk of inducing hyperthyroidism.

A composition administered to sick animals is regarded as a medicament. Therefore the subject matter of claims 1-7, 9-12, 15,16 is not new.

The present application does not meet the criteria of Article 33(1) PCT, because the 3.) subject-matter of claims 8,13,14 does not involve an inventive step in the sense of Article 33(3) PCT.

The subject matter of claims 8,13,14 differs in the addition of thyroxine. The problem to be solved by this difference may be regarded as to provide a further medicament for the treatment of hypothyroidism. The addition of compound to be known for the same treatment is a matter of routine for the skilled person.

It has to be noted that no unexpected effect has been shown for the addition of thyroxin. Additionally no data are provided for the alleged oral activity of the defined formulations.